ISSN: 1874-4346

## SUPPLEMENTARY MATERIAL

**OPEN ACCESS** 

## Challenges of Clinical Decision-making in Emergency Nursing: An Integrative Review



Mohammad Gholipour<sup>1</sup>, Abbas Dadashzadeh<sup>1,2,\*</sup>, Faranak Jabarzadeh<sup>1</sup> and Parvin Sarbakhsh<sup>3</sup>

<sup>1</sup>Department of Medical Surgical Nursing, Faculty of Nursing and Midwifery, Tabriz University of Medical Sciences, Tabriz, Iran

<sup>2</sup>Department of Medical Surgical Nursing, Faculty of Nursing and Midwifery, Qum University of Medical Sciences, Oum, Iran

<sup>3</sup>Health and Environment Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

 $\ ^{\odot}$  2025 The Author(s). Published by Bentham Open.

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



\*Address correspondence to this author at the Department of Medical Surgical Nursing, Faculty of Nursing and Midwifery, Tabriz University of Medical Sciences, Tabriz, Iran and Department of Medical Surgical Nursing, Faculty of Nursing and Midwifery, Qum University of Medical Sciences, Qum, Iran; Tel: +989144090012; E-mail: dadashzadehab@gmail.com

Published: April 08, 2025



Send Orders for Reprints to reprints@benthamscience.net

Cite as: Gholipour M, Dadashzadeh A, Jabarzadeh F, Sarbakhsh P. Challenges of Clinical Decision-making in Emergency Nursing: An Integrative Review. Open Nurs J, 2025; 19: e18744346378311. http://dx.doi.org/10.2174/0118744346378311250320070725

## PRISMA 2020 Checklist

Section and Topic	Item #	Checklist Item	Location where Item is Reported	
TITLE	-		-	
Title	1	Identify the report as a systematic review.	P 1	
ABSTRACT				
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	P 1	
INTRODUCTION				
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	P 3	
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	P 4	
METHODS				
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	P 4	
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Р3	
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Р3	
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	P 4	
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	P5	

Section and Topic	Item #	Checklist Item	Location where Item is Reported
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	P4-p5
Data items	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Table1
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	P 5
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	-
	13a	Describe the processes used to decide which studies were eligible for each synthesis ( $e.g.$ tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	P4-p5
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	P4-p5
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	P5
Synthesis methods	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	-
	13e	Describe any methods used to explore possible causes of heterogeneity among study results ( $e.g.$ subgroup analysis, meta-regression).	-
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	-
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	-
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	-
RESULTS			-
Study coloction	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	figure
Study selection	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	P 5
Study characteristics	17	Cite each included study and present its characteristics.	Table1
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	P 5
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	-
	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	-
Results of syntheses	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	-
	20c	the methods used to assess risk of bias in the included studies, including details of the tool(s) used, any reviewers assessed each study and whether they worked independently, and if applicable, details mation tools used in the process.  For each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or ration of results.  To reach outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or ration of results.  To early methods required to prepare the data for presentation or synthesis, such as handling of summary statistics, or data conversions.  To early methods used to tabulate or visually display results of individual studies and syntheses.  To early methods used to tabulate or visually display results of individual studies and syntheses.  To early methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis reformed, describe the model(s), method(s) to identify the presence and extent of statistical genetity, and software package(s) used.  To early methods used to explore possible causes of heterogeneity among study results (e.g. subgroup so, meta-regression).  To early methods used to explore possible causes of heterogeneity among study results (e.g. subgroup so, meta-regression).  To early methods used to assess risk of bias due to missing results in a synthesis (arising from any biases).  To early methods used to assess certainty (or confidence) in the body of evidence for an outcome.  To early methods used to assess certainty (or confidence) in the body of evidence for an outcome.  To early the subject of the search and selection process, from the number of records identified in the tot the number of studies included in the review, ideally using a flow diagram.  To early the subject of the search and selection process, from the number of records identified in the tot the number of studies included in the review, ideally using a flow diagram.  To early the subject of the search and selection process, from the	-
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	-
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	-
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	-
DISCUSSION			-
	23a	Provide a general interpretation of the results in the context of other evidence.	P9-p10
	Specify the methods used to assess risk of hiss in the included studies, including details of the tool(s) used, bow many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.    12	P5	
Discussion			P4-p5
		·	P11
OTHER INFORMATIO		A TOTAL PART OF THE PART OF TH	-
Registration and protocol			-
	24b	5	P11
			-
Support		Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors	P11
Composing interests	26		P11
Competing interests  Availability of data,	20		L11
code and other materials	27	forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	P11
D 1/7 1/7	· 15 D	December DM Routron I Hoffmann TC Mulrow CD at al. The DDISMA 2020 statement, an undated quidelin	

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71 For more information, visit: http://www.prisma-statement.org/